Frailty Syndrome: Clinical Trials

3 trials for Frailty Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 unknown. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 1, Recruiting 1, Unknown 1

Follow Frailty Syndrome: new trials by email Literature Review of Frailty Syndrome trials Research Report on Frailty Syndrome

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging
Nicotinamide Riboside (NR), Placebo - Frailty, Frail Elderly Syndrome
Phase 2RecruitingHaukeland University Hospital1002025-01-012025-01-20
Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls
Nicotinamide, Placebo - Frailty, Fall
Phase 2UnknownUniversity of Chile602024-05-212024-06-20
Ghrelin Plus Strength Training in Frail Elderly Study
Ghrelin, Placebo - Frailty Syndrome
Phase 2CompletedUniversity of Pennsylvania162013-07-012019-12-11

Narrower conditions

Frailty (3)  ·  Motor Activity (2)  ·  Sarcopenia (1)  ·  Weight Loss (1)

Broader conditions

Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Behavior (2)  ·  Atrophy (1)  ·  Body Weight (1)  ·  Body Weight Changes (1)  ·  Muscular Atrophy (1)  ·  Nervous System Diseases (1)  ·  Neurologic Manifestations (1)  ·  Neuromuscular Manifestations (1)  ·  Pathological Conditions, Anatomical (1)  ·  Signs and Symptoms (1)

Interventions

Ghrelin (1)  ·  Niacinamide (1)  ·  nicotinamide-beta-riboside (1)

Sponsors

Haukeland University Hospital (1)  ·  University of Chile (1)  ·  University of Pennsylvania (1)

Countries

Chile (1)  ·  Norway (1)  ·  United States (1)

Top investigators

Anne R. Cappola, M.D.,Sc.M. (1)  ·  Charalampos Tzoulis, PhD (1)  ·  Felipe H Salech Morales, MD-PhD (1)

NIH funding

2023 (1)